Cover Image

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients

Aim: This study aimed to report the efficacy and safety of trans-arterial chemoembolization (TACE) plus lenvatinib and camrelizumab in patients with advanced hepatocellular carcinoma (HCC).Methods: This retrospective study enrolled 22 patients with advanced HCC from March 2018 to December 2019. All...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juanfang Liu (Author), Zhen Li (Author), Wenguang Zhang (Author), Huibin Lu (Author), Zhanguo Sun (Author), Guozheng Wang (Author), Xinwei Han (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023)

Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population
by: Shuzhao Jia, et al.
Published: (2020)

Biliary complications after transcatheter arterial chemoembolization for hepatocellular carcinoma
by: Yoon Suk Lee, et al.
Published: (2020)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
by: Qing-Yun Xie, et al.
Published: (2022)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Rupture of hepatocellular carcinoma after transcatheter arterial chemoembolization: A case report
by: Hye Hyeon Moon, et al.
Published: (2021)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023)

Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan
by: Hiroki Higashihara, et al.
Published: (2021)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal
by: Degang Kong, et al.
Published: (2020)

Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma
by: Zizhuo Wang, et al.
Published: (2024)

Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis
by: Zhao Q, et al.
Published: (2016)

Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
by: Byeong Geun Song, et al.
Published: (2024)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
by: Wu Y, et al.
Published: (2023)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022)
by: Cong-Cong Wang, et al.
Published: (2023)

Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022)

Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
by: Toshiyuki Irie, et al.
Published: (2020)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
by: Yin L, et al.
Published: (2022)

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma
by: Ya-Qing Zhang MM, et al.
Published: (2017)

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma
by: Ya-Qing Zhang MM, et al.
Published: (2017)

Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma
by: Haitao Liu, et al.
Published: (2023)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
by: Yukari Matsumoto, et al.
Published: (2022)

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma
by: Rachel Sally, BA, et al.
Published: (2021)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
by: Landon L. Chan, et al.
Published: (2024)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020)

Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma
by: Chiu SH, et al.
Published: (2020)

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma
by: Risako Ozawa, et al.
Published: (2024)

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
by: Nicoletta Colombo, et al.
Published: (2023)

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
by: Xiaomi Li, et al.
Published: (2023)

Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review
by: Cheng Xue, et al.
Published: (2024)

Role of drug-eluting beads versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
by: Mahmoud Abu Elfadl, et al.
Published: (2019)

Efficacy of Selective Internal Radiation Therapy for Hepatocellular Carcinoma Post-Incomplete Response to Chemoembolization
by: Salma Binzaqr, et al.
Published: (2023)

Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
by: Jiwon Yang, et al.
Published: (2024)